Latest Insider Transactions at Stoke Therapeutics, Inc. (STOK)
This section provides a real-time view of insider transactions for Stoke Therapeutics, Inc. (STOK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Stoke Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Stoke Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2024
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
6,786
-9.88%
|
$81,432
$12.99 P/Share
|
|
Dec 09
2024
|
Jonathan Allan GENERAL COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
13,666
-20.61%
|
$177,658
$13.34 P/Share
|
|
Dec 09
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,586
-5.46%
|
$31,032
$12.99 P/Share
|
|
Dec 06
2024
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
6,170
-8.24%
|
$74,040
$12.78 P/Share
|
|
Dec 06
2024
|
Jonathan Allan GENERAL COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
9,696
-21.62%
|
$116,352
$12.78 P/Share
|
|
Dec 06
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
13,945
-22.76%
|
$167,340
$12.78 P/Share
|
|
Dec 03
2024
|
Edward M. Md Kaye CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,500
+26.09%
|
-
|
|
Dec 03
2024
|
Jonathan Allan GENERAL COUNSEL & CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+11.8%
|
-
|
|
Dec 03
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.03%
|
-
|
|
Dec 02
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-16.32%
|
$120,000
$12.07 P/Share
|
|
Dec 02
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.03%
|
$0
$0.6 P/Share
|
|
Dec 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
48,792
+48.76%
|
-
|
|
Dec 01
2024
|
Edward M. Md Kaye CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,591
+30.76%
|
-
|
|
Dec 01
2024
|
Jonathan Allan GENERAL COUNSEL & CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
33,927
+46.63%
|
-
|
|
Nov 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-80.1%
|
$120,000
$12.68 P/Share
|
|
Nov 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.47%
|
$0
$0.6 P/Share
|
|
Oct 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-80.1%
|
$120,000
$12.06 P/Share
|
|
Oct 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.47%
|
$0
$0.6 P/Share
|
|
Sep 19
2024
|
Skorpios Trust > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,937,500
-17.87%
|
$27,125,000
$14.05 P/Share
|
|
Sep 03
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-47.37%
|
$150,000
$15.17 P/Share
|
|
Sep 03
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.47%
|
$0
$0.6 P/Share
|
|
Aug 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-80.1%
|
$140,000
$14.58 P/Share
|
|
Aug 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.47%
|
$0
$0.6 P/Share
|
|
Jul 02
2024
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,500
-99.34%
|
$32,500
$13.5 P/Share
|
|
Jul 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-80.1%
|
$130,000
$13.75 P/Share
|
|
Jul 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.47%
|
$0
$0.6 P/Share
|
|
Jun 03
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-41.63%
|
$150,000
$15.5 P/Share
|
|
Jun 03
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.47%
|
$0
$0.6 P/Share
|
|
May 20
2024
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-100.0%
|
$750,000
$15.39 P/Share
|
|
May 20
2024
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$0
$0.4 P/Share
|
|
May 20
2024
|
Jonathan Allan GENERAL COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
8,599
-76.8%
|
$128,985
$15.04 P/Share
|
|
May 20
2024
|
Jonathan Allan GENERAL COUNSEL & CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
8,599
+43.44%
|
$60,193
$7.07 P/Share
|
|
May 20
2024
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
42,350
-33.1%
|
$635,250
$15.72 P/Share
|
|
May 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-80.1%
|
$110,000
$11.37 P/Share
|
|
May 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.47%
|
$0
$0.6 P/Share
|
|
Apr 17
2024
|
Skorpios Trust > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,600,000
-24.92%
|
$39,600,000
$11.6 P/Share
|
|
Apr 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
9,426
-79.14%
|
$122,538
$13.23 P/Share
|
|
Apr 01
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
442
+3.58%
|
$0
$0.6 P/Share
|
|
Apr 01
2024
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
61,329
-99.67%
|
$797,277
$13.42 P/Share
|
|
Apr 01
2024
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+44.91%
|
$0
$0.4 P/Share
|
|
Mar 28
2024
|
Jonathan Allan GENERAL COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
5,126
-34.39%
|
$66,638
$13.5 P/Share
|
|
Mar 19
2024
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
4,116
-16.56%
|
$24,696
$6.1 P/Share
|
|
Mar 19
2024
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
11,150
-13.85%
|
$66,900
$6.1 P/Share
|
|
Mar 19
2024
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,116
-26.65%
|
$24,696
$6.1 P/Share
|
|
Mar 19
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,116
-26.41%
|
$24,696
$6.1 P/Share
|
|
Mar 19
2024
|
Jonathan Allan GENERAL COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
2,349
-23.32%
|
$14,094
$6.1 P/Share
|
|
Mar 15
2024
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,100
+34.51%
|
-
|
|
Mar 15
2024
|
Edward M. Md Kaye CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,500
+30.6%
|
-
|
|
Mar 15
2024
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,100
+45.89%
|
-
|
|
Mar 15
2024
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
13,100
+45.67%
|
-
|